REDWOOD CITY, Calif., Nov. 29, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present seven Oncotype DX® studies at the 39th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10, 2016. The study findings reinforce the Company's leadership in individualizing breast cancer treatment decisions and the value of the Oncotype DX test in various stages of the disease. Presentations include:
Results from a study based on the Surveillance, Epidemiology, and End Results (SEER) registry program of the National Cancer Institute (NCI), the premier source of cancer statistics in the United States. The study assessed breast cancer-specific mortality in patients with poorly differentiated tumors who were treated based on their Oncotype DX Breast Recurrence Score™ results.
A gene discovery study conducted in collaboration with SWOG, an NCI cooperative group, that analyzed molecular predictors of early breast cancer outcomes, highlighting Genomic Health's leadership in using next-generation sequencing for gene expression analysis.
A comparison of the use of commonly available clinical predictive tools and physician estimates vs. the Oncotype DX Breast DCIS Score™ to determine ipsilateral breast event risks in patients with ductal carcinoma in situ (DCIS) post-lumpectomy.
A study design for an ongoing study evaluating the use of the Breast Recurrence Score results in patients with metastatic breast cancer at the time of first diagnosis.
A summary of the unprecedented amount of clinical outcomes evidence from more than 50,000 patients across multiple large studies.
A multi-center trial evaluating the use of Oncotype DX to select neoadjuvant therapy for early-stage breast cancer.
A decision impact study demonstrating the value of using Oncotype DX in eligible patients in France.
Complete results from the studies will be announced in accordance with the SABCS embargo policy. Following are details for each presentation (all times are in Central Standard Time):
Wednesday, December 7
Abstract: P1-11-02 Poster: "A comparison of models (physician, the Van Nuys prognostic index, the Memorial-Sloan-Kettering Cancer Center DCIS nomogram) to predict ipsilateral breast events in patients with ductal carcinoma in situ (DCIS) of the breast after breast-conserving surgery failed to replicate results of the oncotype DCIS recurrence score" Authors: Leonard C, Lei R, Antell A, Nowels M, Fryman S, Howell K, Dennis C. Location: Hall 1 Time: 5 – 7 p.m.
Thursday, December 8
Abstract: P2-10-04 Poster: "Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial" Authors: Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White, Jr. RL, Granfortuna J, Hopkins JO, Oldham D, Rodriguez A, Sing AP. Location: Hall 1 Time: 7:30 – 9 a.m.
Friday, December 9
Abstract: PD7-06 Poster Discussion: "SEER study of breast cancer-specific mortality in patients with poorly differentiated tumors treated based on Recurrence Score results" Authors: Petkov VI, Miller DP, Howlader N, Baehner FL, Penberthy L, Shak S. Location: Stars at Night Ballroom 1 and 2 (Level 3) Time: 7:30 – 9 a.m.
Abstract: PD7-07 Poster Discussion: "Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814" Authors: Albain KS, Crager MR, Barlow WE, Baehner FL, Bergamaschi A, Rae JM, Ravdin PM, Tripathy D, Gralow JR, Livingston RB, Osborne CK, Ingle JN, Pritchard KI, Davidson NE, Carey LA, Cherbavaz DB, Sing AP, Shak S, Hortobagyi GN, Hayes DF. Location: Stars at Night Ballroom 1 and 2 (Level 3) Time: 7:30 – 9 a.m.
Abstract: OT3-04-04 Poster: "21-gene recurrence score® in patients with primary metastatic ER+ HER2- breast cancer" Authors: Barinoff J, Anastasiadou L, Brandi C, Junker-Stein A, Silbermann J, Langenfeld M, Fortmann C, Thill M. Location: Hall 1 Time: 5 – 7 p.m.
Saturday, December 10
Abstract: P6-09-08 Poster: "Real-world clinical experience and outcomes in patients with early-stage breast cancer (EBC) treated according to the 21-gene Recurrence Score® (RS) result" Authors: Sing AP, Rothney M, Svedman C, Shak S, Baehner FL. Location: Hall 1 Time: 7:30 – 9 a.m.
Abstract: P6-07-28 Poster: "The 21-gene assay in the decision impact assessment of ER+, HER2- breast cancer: A French real life prospective study" Authors: Gligorov J, Dohollou N, Mouysset JL, Laplaige P, Fignon A, Lafuma A, Michaud P. Location: Hall 1 Time: 7:30 – 9 a.m.
About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. With more than 700,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com or www.MyBreastCancerTreatment.org.
About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 700,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select assay. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.